DK3630114T3 - Migalastat til behandling af patienter med fabrys sygdom, der har nedsat nyrefunktion - Google Patents
Migalastat til behandling af patienter med fabrys sygdom, der har nedsat nyrefunktion Download PDFInfo
- Publication number
- DK3630114T3 DK3630114T3 DK18733415.6T DK18733415T DK3630114T3 DK 3630114 T3 DK3630114 T3 DK 3630114T3 DK 18733415 T DK18733415 T DK 18733415T DK 3630114 T3 DK3630114 T3 DK 3630114T3
- Authority
- DK
- Denmark
- Prior art keywords
- migalastat
- fabry
- patients
- disease
- treatment
- Prior art date
Links
- 208000024720 Fabry Disease Diseases 0.000 title 1
- 230000003247 decreasing effect Effects 0.000 title 1
- 230000003907 kidney function Effects 0.000 title 1
- LXBIFEVIBLOUGU-DPYQTVNSSA-N migalastat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O LXBIFEVIBLOUGU-DPYQTVNSSA-N 0.000 title 1
- 229950007469 migalastat Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762512458P | 2017-05-30 | 2017-05-30 | |
| US201862626953P | 2018-02-06 | 2018-02-06 | |
| PCT/US2018/035032 WO2018222655A1 (en) | 2017-05-30 | 2018-05-30 | Methods of treating fabry patients having renal impairment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3630114T3 true DK3630114T3 (da) | 2024-01-29 |
Family
ID=65803261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18733415.6T DK3630114T3 (da) | 2017-05-30 | 2018-05-30 | Migalastat til behandling af patienter med fabrys sygdom, der har nedsat nyrefunktion |
Country Status (12)
| Country | Link |
|---|---|
| EP (8) | EP4062915A1 (da) |
| CN (2) | CN111278438A (da) |
| DK (1) | DK3630114T3 (da) |
| ES (1) | ES2970419T3 (da) |
| FI (1) | FI3630114T3 (da) |
| HR (1) | HRP20240061T1 (da) |
| LT (1) | LT3630114T (da) |
| PL (1) | PL3630114T3 (da) |
| PT (1) | PT3630114T (da) |
| RS (1) | RS65230B1 (da) |
| SI (1) | SI3630114T1 (da) |
| TW (3) | TWI795408B (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020327019A1 (en) * | 2019-08-07 | 2022-03-03 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| SI2533050T1 (sl) * | 2006-05-16 | 2014-07-31 | Amicus Therapeutics, Inc. | MoĹľnosti zdravljenja Fabrijeve bolezni |
| EP2142197A4 (en) | 2007-03-30 | 2010-11-10 | Amicus Therapeutics Inc | PROCESS FOR THE TREATMENT OF FABRY DISEASE USING PHARMACOLOGICAL CHAPERONS |
| US9999618B2 (en) * | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| US9056101B2 (en) * | 2007-04-26 | 2015-06-16 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| PT2252313E (pt) | 2008-02-12 | 2015-08-26 | Amicus Therapeutics Inc | Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas |
| CN103974619B (zh) * | 2011-03-11 | 2017-02-15 | 阿米库斯治疗学公司 | 治疗法布里病的给药方案 |
| US20120283290A1 (en) * | 2011-05-06 | 2012-11-08 | Amicus Therapeutics Inc. | Quantitation of gl3 in urine |
| WO2019017938A1 (en) * | 2017-07-19 | 2019-01-24 | Amicus Therapeutics, Inc. | TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES |
-
2018
- 2018-05-30 EP EP22165647.3A patent/EP4062915A1/en active Pending
- 2018-05-30 SI SI201831052T patent/SI3630114T1/sl unknown
- 2018-05-30 FI FIEP18733415.6T patent/FI3630114T3/fi active
- 2018-05-30 EP EP18733415.6A patent/EP3630114B1/en active Active
- 2018-05-30 EP EP23189734.9A patent/EP4245366A3/en active Pending
- 2018-05-30 EP EP24164126.5A patent/EP4374918A2/en active Pending
- 2018-05-30 ES ES18733415T patent/ES2970419T3/es active Active
- 2018-05-30 TW TW107118443A patent/TWI795408B/zh active
- 2018-05-30 EP EP23219922.4A patent/EP4327868A2/en not_active Withdrawn
- 2018-05-30 CN CN201880043564.XA patent/CN111278438A/zh active Pending
- 2018-05-30 EP EP23219949.7A patent/EP4324522A3/en active Pending
- 2018-05-30 DK DK18733415.6T patent/DK3630114T3/da active
- 2018-05-30 EP EP22165669.7A patent/EP4062916A1/en active Pending
- 2018-05-30 TW TW110119149A patent/TWI775453B/zh active
- 2018-05-30 CN CN202311285883.0A patent/CN117357524A/zh active Pending
- 2018-05-30 TW TW112104527A patent/TW202322814A/zh unknown
- 2018-05-30 PT PT187334156T patent/PT3630114T/pt unknown
- 2018-05-30 HR HRP20240061TT patent/HRP20240061T1/hr unknown
- 2018-05-30 PL PL18733415.6T patent/PL3630114T3/pl unknown
- 2018-05-30 RS RS20240113A patent/RS65230B1/sr unknown
- 2018-05-30 LT LTEPPCT/US2018/035032T patent/LT3630114T/lt unknown
- 2018-05-30 EP EP23219933.1A patent/EP4327869A3/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2970419T3 (es) | 2024-05-28 |
| FI3630114T3 (fi) | 2024-01-30 |
| PT3630114T (pt) | 2024-02-01 |
| EP4327869A3 (en) | 2024-05-22 |
| TW202322814A (zh) | 2023-06-16 |
| EP3630114A1 (en) | 2020-04-08 |
| CN117357524A (zh) | 2024-01-09 |
| EP4062916A1 (en) | 2022-09-28 |
| EP4245366A3 (en) | 2023-11-29 |
| EP4324522A3 (en) | 2024-05-22 |
| EP4327869A2 (en) | 2024-02-28 |
| EP4374918A2 (en) | 2024-05-29 |
| EP4327868A2 (en) | 2024-02-28 |
| EP4245366A9 (en) | 2023-12-06 |
| TWI775453B (zh) | 2022-08-21 |
| PL3630114T3 (pl) | 2024-03-25 |
| EP3630114B1 (en) | 2023-11-01 |
| TWI795408B (zh) | 2023-03-11 |
| TW202140000A (zh) | 2021-11-01 |
| CN111278438A (zh) | 2020-06-12 |
| SI3630114T1 (sl) | 2024-03-29 |
| TW201900165A (zh) | 2019-01-01 |
| EP4062915A1 (en) | 2022-09-28 |
| EP4245366A2 (en) | 2023-09-20 |
| LT3630114T (lt) | 2024-02-12 |
| EP4324522A2 (en) | 2024-02-21 |
| RS65230B1 (sr) | 2024-03-29 |
| HRP20240061T1 (hr) | 2024-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3386511T3 (da) | Fremgangsmåder til behandling af huntingtons sygdom | |
| DK3364997T3 (da) | Aspartoacylase genterapi til behandling af canavans sygdom | |
| DK3340981T3 (da) | Aryl, heteroaryl og heterocykliske forbindelser til behandling af medicinske forstyrrelser | |
| DK3516060T3 (da) | Antisense-oligonukleotider til behandling af øjensygdom | |
| DK3789501T3 (da) | Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom | |
| DK3399962T3 (da) | Oftalmisk sammensætning til behandling af tør øjensygdom | |
| DK3134386T3 (da) | Isoindolin-1-on-derivater med kolinerg muscarin-m1-receptor-positiv allosterisk modulatoraktivitet til behandling af alzheimers sygdom | |
| DK2968218T3 (da) | Kombination til behandling af parkinsons sygdom | |
| DK3700604T3 (da) | Systemer til selektiv okkludering af øvre hulvene til behandling af hjertelidelser | |
| DK3668513T3 (da) | Pyruvatkinase-aktiveringsmidler til anvendelse til behandling af blodsygdomme | |
| DK3720433T3 (da) | Bis-cholin-tetrathiomolybdat til behandling af wilsons sygdom | |
| DK3240538T3 (da) | Anvendelse af masitinib til behandling af en underpopulation af patienter med amyotrofisk lateralsklerose | |
| DK3749308T3 (da) | Behandling af patienter med klassisk fabrys sygdom med migalastat | |
| DK3463351T3 (da) | Behandling til parkinsons sygdom | |
| DK3432895T3 (da) | Blodpladepelletlysat til anvendelse til behandling af neurologiske forstyrrelser | |
| DK3277287T3 (da) | Blandinger af humane mælke-oligosaccharider, der omfatter 3 '-o-sialyllactose | |
| DK3833746T3 (da) | Mini-gde til behandlingen af glykogenlagringssygdom iii | |
| DK3373931T3 (da) | Heterocykliske forbindelser til behandling af sygdom | |
| DE112018006114A5 (de) | Kanüle, kanülensystem und blutpumpensystem | |
| IL270715A (en) | Cannula for intravascular blood pump | |
| MA42611A (fr) | Traitement combiné comprenant l'administration de 2-amino-3,5,5-trifluoro-3,4,5,6-tétrahydropyridines | |
| DK3624795T3 (da) | Kondenserede, heteroaromatiske anilinforbindelser til behandling af hudforstyrrelser | |
| DK3630164T3 (da) | Dulaglutid til behandling af kronisk nyresygdom | |
| DK3585327T3 (da) | System til behandling af søvnforstyrret åndedræt | |
| DK3630114T3 (da) | Migalastat til behandling af patienter med fabrys sygdom, der har nedsat nyrefunktion |